185 related articles for article (PubMed ID: 35459391)
21. Osteoporosis in Patients with Chronic Kidney Diseases: A Systemic Review.
Hsu CY; Chen LR; Chen KH
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961953
[TBL] [Abstract][Full Text] [Related]
22. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
Koizumi M; Komaba H; Fukagawa M
Contrib Nephrol; 2013; 180():110-23. PubMed ID: 23652554
[TBL] [Abstract][Full Text] [Related]
23. [Secondary hyperparathyroidism and tertiary hyperparathyroidism chronic renal failure, uremia].
Morio K; Koide K
Nihon Rinsho; 1995 Apr; 53(4):958-64. PubMed ID: 7752492
[TBL] [Abstract][Full Text] [Related]
24. Treatment of hyperphosphatemia: the dangers of aiming for normal PTH levels.
Haffner D; Leifheit-Nestler M
Pediatr Nephrol; 2020 Mar; 35(3):485-491. PubMed ID: 31823044
[TBL] [Abstract][Full Text] [Related]
25. Mineral and bone disorders in patients on dialysis: physiology and clinical consequences.
McCarley PB; Arjomand M
Nephrol Nurs J; 2008; 35(1):59-64. PubMed ID: 18372764
[TBL] [Abstract][Full Text] [Related]
26. CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies.
Reiss AB; Miyawaki N; Moon J; Kasselman LJ; Voloshyna I; D'Avino R; De Leon J
Atherosclerosis; 2018 Nov; 278():49-59. PubMed ID: 30253289
[TBL] [Abstract][Full Text] [Related]
27. Prevention and treatment of renal osteodystrophy in children with chronic renal insufficiency and end-stage renal disease.
Sanchez CP
Semin Nephrol; 2001 Sep; 21(5):441-50. PubMed ID: 11559885
[TBL] [Abstract][Full Text] [Related]
28. The Importance of Phosphate Control in Chronic Kidney Disease.
Tsuchiya K; Akihisa T
Nutrients; 2021 May; 13(5):. PubMed ID: 34069053
[TBL] [Abstract][Full Text] [Related]
29. Dietary Protein Intake and Bone Across Stages of Chronic Kidney Disease.
Stremke ER; Biruete A; Hill Gallant KM
Curr Osteoporos Rep; 2020 Jun; 18(3):247-253. PubMed ID: 32240477
[TBL] [Abstract][Full Text] [Related]
30. Hyperparathyroidism in the maintenance dialysis patient.
Glassford DM; Remmers AR; Sarles HE; Lindley JD; Scurry MT; Fish JC
Surg Gynecol Obstet; 1976 Mar; 142(3):328-32. PubMed ID: 1251311
[TBL] [Abstract][Full Text] [Related]
31. [Parathyroid and bone. Management of parathyroid function and evaluation of bone metabolism in hemodialysis patients].
Goto S; Fukagawa M
Clin Calcium; 2007 Dec; 17(12):1830-4. PubMed ID: 18057657
[TBL] [Abstract][Full Text] [Related]
32. [Effect of Ronghuang Granule on serum FGF23, FGFRs and Klotho in non-dialysis patients with CKD-MBD and kidney deficiency and damp-heat syndrome].
Hu S; Wang D; Zhang R; Cao Y; Jin H; Mao Y; Wei L; Ren K; Zhang X; Wang Y
Nan Fang Yi Ke Da Xue Xue Bao; 2018 Dec; 38(12):1427-1432. PubMed ID: 30613009
[TBL] [Abstract][Full Text] [Related]
33. Parathyroid Hormone: A Uremic Toxin.
Duque EJ; Elias RM; Moysés RMA
Toxins (Basel); 2020 Mar; 12(3):. PubMed ID: 32192220
[TBL] [Abstract][Full Text] [Related]
34. Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure.
Neves KR; Graciolli FG; dos Reis LM; Pasqualucci CA; Moysés RM; Jorgetti V
Kidney Int; 2004 Dec; 66(6):2237-44. PubMed ID: 15569312
[TBL] [Abstract][Full Text] [Related]
35. The role of FGF23 in CKD--with or without Klotho.
Komaba H; Fukagawa M
Nat Rev Nephrol; 2012 Jun; 8(8):484-90. PubMed ID: 22714041
[TBL] [Abstract][Full Text] [Related]
36. [Bone disease in chronic renal failure and its modern therapy].
Dusilová Sulková S
Vnitr Lek; 2011; 57(7-8):620-5. PubMed ID: 21877595
[TBL] [Abstract][Full Text] [Related]
37. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
38. The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease.
Graciolli FG; Neves KR; Barreto F; Barreto DV; Dos Reis LM; Canziani ME; Sabbagh Y; Carvalho AB; Jorgetti V; Elias RM; Schiavi S; Moysés RMA
Kidney Int; 2017 Jun; 91(6):1436-1446. PubMed ID: 28318623
[TBL] [Abstract][Full Text] [Related]
39. Personalized Management of Bone and Mineral Disorders and Precision Medicine in End-Stage Kidney Disease.
Jovanovich A; Kendrick J
Semin Nephrol; 2018 Jul; 38(4):397-409. PubMed ID: 30082059
[TBL] [Abstract][Full Text] [Related]
40. Treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Komaba H; Tanaka M; Fukagawa M
Intern Med; 2008; 47(11):989-94. PubMed ID: 18520108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
